Naloxone Affordability Act of 2023

The Naloxone Affordability Act of 2023 requires the Government Accountability Office (GAO) to study how naloxone - a medication that reverses opioid overdoses - is covered by health insurance and the costs patients face when purchasing it. The study will specifically examine whether naloxone should be covered as an over-the-counter product under group health plans, Medicare, and Medicaid, and analyze out-of-pocket expenses for consumers. The GAO must complete this study and submit a report to Congress within one year of the bill’s enactment. This bill does not change current coverage or costs but aims to provide Congress with data to inform future policy decisions about naloxone access.